Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

SOUTHAMPTON, England, April 21 /PRNewswire/ -- Vantia Therapeutics, a company developing novel small molecule drugs targeting large underserved medical markets, today announces the appointment of Rachel Morten as Head of Regulatory Affairs.

Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries. Most recently an independent regulatory affairs consultant, Rachel has also served as Senior Director, Group Head Regulatory Affairs for the international CRO Averion International Ltd (previously Hesperion). Previously Rachel founded ChapelPharma a regulatory consultancy that was acquired by Hesperion in 2004.

Dr Jim Phillips, CEO of Vantia Therapeutics, said: "Rachel brings to Vantia years of experience across all regulatory aspects of the global development of new chemical entities from pre-clinical through to Phase III. She is an excellent addition to our already high-quality management team at Vantia and I look forward to working with her as our clinical and pre-clinical pipeline continues to mature."

Rachel Morten, Head of Regulatory Affairs, said: "Vantia has already made great progress with its pipeline, with the Phase IIa trial of VA106483 for nocturia recently completed and dosing complete in the Phase I trial of VA111913 for dysmenorrhoea. These products target conditions which affect millions of people and are poorly served by current treatments. It is the quality of these programmes, the pre-clinical pipeline and the drug discovery engine that made the opportunity of joining the team at Vantia so exciting."

Notes to Editors

About Vantia Therapeutics:

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets. Its rapidly advancing clinical pipeline includes VA106483 for nocturia
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: ... early-stage algae bioactive compounds and metabolic processes, is pleased to ... board of directors. Ms. Nola E. Masterson , a ... joined the board effective September 17, 2014. ... to join our board," states Andrew Dahl , President ...
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... NewsMakers in the Biotech Industry conference on Friday, September ... Broadway Hotel & Conference Center in New York ... accessed at www.meipharma.com . A replay will be available ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global N-acetylcysteine Industry Report 2014 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... increase its number of new technology-based companies, but ... part of their growth strategies, according to a ... technology transfer and commercialization organizations. , ,Representatives from ... Center for Advanced Technology & Innovation (CATI), and ...
... Plan , Affinity Health Systems health plan provider in ... availability of new online services for NHPs providers, members, ... management system. , ,NHP will launch the product suite ... Starting this summer, NHPs providers will be able to ...
... Louis Loeffler , technology coordinator for the Sun Prairie Area ... in education at a meeting of the World Future ... Americans than ever are getting a public education, he said, ... with the developing world. New technologies can also offer better ...
Cached Biology Technology:Three Wisconsin approaches to technology transfer and commercialization 2Three Wisconsin approaches to technology transfer and commercialization 3Three Wisconsin approaches to technology transfer and commercialization 4Three Wisconsin approaches to technology transfer and commercialization 521st century skills, the future of technology and education 221st century skills, the future of technology and education 3
(Date:9/19/2014)... biology professor will study multifunctional and specialized spinal ... a National Science Foundation grant in the amount ... Berkowitz, professor in the Department of Biology, OU ... the differences between the multifunctional and specialized spinal ... use and what connections they make. Berkowitz ...
(Date:9/19/2014)... you are a species which over thousands of years has ... to a substance that makes the cold dangerous for you. ... Enchytraeus albidus , and the cold provoking substance, called nonylphenol, ... , Nonylphenol is suspected of being a endocrine disruptor, but ... inhibits the worm,s ability to protect the cells in its ...
(Date:9/19/2014)... shows that legume plants regulate their symbiotic relationship ... are transmitted through the plant structure from leaves ... bacteria-holding nodules in the roots. This collaborative study ... for Basic Biology, the Graduate University for Advanced ... Resource Science in Japan. , Legumes, an ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3For legume plants, a new route from shoot to root 2
... in preventing some of the stresses of open surgery on ... and organ dysfunction. Laparoscopy is a type of surgery in ... By adding another gas to the carbon dioxide used ... University Medical Center have found they can preserve more normal ...
... that are associated with the health of the human ... scientists from 63 centres in Europe and Australia sheds ... The new findings provide hope for better treatment ... and asthma. In the past it has been difficult ...
... FORT COLLINS, COWild Malus orientalis species of wild ... applesare native to the Middle East and Central Asia. ... M. orientalis varieties from Georgia and Armenia ... narrows the large population and establishes a core collection ...
Cached Biology News:Gas improves blood flow and organ status during minimally invasive surgery 2New genes for lung disease discovered 2Understanding apples' ancestors 2